The CF Foundation expressed support to the Council of the District of Columbia for B25-0124, Prior Authorization Reform Amendment Act of 2023, which makes several important reforms to the prior authorization process.
Site Search
An ad hoc coalition of patient advocacy organizations sends a letter to Governor DeSantis asking the state to address the redetermination process and the unnecessary loss of coverage for children.
The CF Foundation sent a letter of support to Ohio’s Public Health Policy Committee supporting House Bill 177, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to the state’s Department of Human Services, the Foundation supported Pennsylvania’s request to change provisions of its Medicaid program, including continuous eligibility for children under 6 and services for health-related social needs.
The Cystic Fibrosis Foundation provided comments to the Patient Centered Outcomes Research Institute on their draft landscape of patient-centered economic outcomes that provides recommendations to researchers seeking to understand the economic impacts of living with a disease.
In comments to the Department of Health and Human Services, the Cystic Fibrosis Foundation provided feedback on Notice of Benefit and Payment Parameters for 2025, focusing on the standards of benefits offered in Marketplace plans with a particular emphasis on updating the drug benefit to reflect patients' evolving needs and to
In comments responding to the Department of Health and Human Services’ Notice of Benefits and Payment Parameters for 2025, the Partnership for Protecting Coverage proposed standards for issuers and Marketplaces, as well as requirements for agents, brokers, web-brokers, direct enrollment entities, and assisters that help Marketplace consumers.
In response to a request for information from the U.S. Senate Committee on Health, Education, Labor, and Pensions, the Foundation called for novel, innovative coverage models to ensure access of these critical therapies when they become available to people with cystic fibrosis.
The Cystic Fibrosis Foundation joined the coalition in an amicus brief and related statement to explain how the court’s decision would threaten patients’ and providers’ ability to rely on the U.S. Food and Drug Administration’s decisions regarding drug safety.
In a letter to the Illinois General Assembly, the CF Foundation provides feedback on HB 4472 which would establish an affordability board with the goal to improve access to and affordability of care for Illinoisans.